(NASDAQ: AMLX) Amylyx Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.11%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.32%.
Amylyx Pharmaceuticals's earnings in 2026 is -$144,735,000.On average, 11 Wall Street analysts forecast AMLX's earnings for 2026 to be -$153,469,493, with the lowest AMLX earnings forecast at -$177,654,976, and the highest AMLX earnings forecast at -$92,851,033. On average, 10 Wall Street analysts forecast AMLX's earnings for 2027 to be -$157,316,179, with the lowest AMLX earnings forecast at -$172,238,666, and the highest AMLX earnings forecast at -$104,457,412.
In 2028, AMLX is forecast to generate -$82,305,809 in earnings, with the lowest earnings forecast at -$137,574,281 and the highest earnings forecast at $0.